Assessing brain atrophy by measuring cerebral gray matter has gained particular interest in MS for several reasons. First, the volume of gray matter is less susceptible to external factors such as inflammation; second, gray matter atrophy may precede the onset of MS symptoms, and third, it may help predict some MS clinical disabilities.
Gilenya is an approved RRMS therapy marketed by Switzerland’s Novartis. In Phase 3 clinical trials, Gilenya had a positive effect on MS-related brain lesions measured by magnetic resonance imaging (MRI). The drug also slowed the rate of whole brain atrophy.
In the latest study by Brigham and Young Women’s Hospital’s Partners MS Center, researchers investigated the effects of Gilenya in cerebral gray matter atrophy in 53 RRMS patients being followed up for at least two years. Of the 53 patients, 24 received Gilenya (0.5 mg once daily) during the two-year observation period; the remaining 29 did not.
All patients underwent baseline, one-year and two-year follow-up brain MRIs to assess brain atrophy. Researchers measured two parameters: brain parenchymal fraction and cortical gray matter fraction. They also analyzed patients’ T2 lesion volume and gadolinium-enhancing lesions in the brain.
The analysis showed that after two years, cortical gray matter fraction decreased in untreated patients, while in the Gilenya-treated group it remained stable.
Additionally, patients treated with Gilenya had a slower rate of T2 lesion volume change and showed a significant decrease in the number of gadolinium-enhancing lesions over the two years. The untreated group also saw a decrease in these lesions, but only during the second year.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?